HMNC Brain Health has completed patient randomization for its Phase 2b OLIVE trial, investigating the efficacy and safety of...

Totus Medicines initiated an expansion study for TOS-358, a first-in-class covalent PI3Kα inhibitor, after a successful Phase 1 trial....

Immunis, Inc., a clinical-stage biotech company, secured $25 million in Series A-1 funding to advance two Phase 2 clinical...

Sage Therapeutics announced its 2025 strategic focus, centering on the growth of ZURZUVAE (zuranolone) for postpartum depression (PPD) and...

Synchron, a brain-computer interface (BCI) company, is partnering with NVIDIA to enhance its implantable BCI technology using the NVIDIA...

Ashvattha Therapeutics secured up to $50 million in extended Series B funding, led by Tribe Capital and existing investors...

Artelo Biosciences has initiated a Phase 1 clinical trial of ART26.12, its lead FABP5 inhibitor, marking the first time...

NeuroSigma, Inc. announced the completion of enrollment for the ATTENS trial, a multicenter, double-blind, placebo-controlled study evaluating the effectiveness...

Rakovina Therapeutics has achieved a significant milestone by developing a shortlist of AI-generated molecules targeting ATR, designed for central...

ORIC Pharmaceuticals announced encouraging early safety and efficacy data from a Phase 1b trial of ORIC-944 combined with apalutamide...